News

Minaris Regenerative Medicine is proud to share current and past news and announcements from its over twenty years of experience. Please see below for our press releases and announcements.

    *This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, fomerly PCT or PCT Cell Therapy Services), apceth Biopharma GmbH, and Hitachi Chemical Co., Ltd. have been renamed Minaris Regenerative Medicine and are part of the Resonac Group.
    October 5, 2018

    apceth to Manufacture First Potential One-Time Gene Therapy for Transfusion Depended β-thalassemia

    Munich, Germany, Oct 5th, 2018 - apceth Biopharma GmbH, a leading company for the development and manufacturing of cell and gene therapeutics, congratulates its partner bluebird bio on the acceptance and validation of its market authorization application by the European Medicines Agency (EMA). bluebird bio has applied for market authorization of its investigational LentiGlobin™ gene therapy for ...
    October 1, 2018

    Hitachi Chemical Advanced Therapeutics Solutions Signs Three-Year Agreement with GSK

    Allendale, NJ, United States, October 1, 2018 - Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS) announced today that they have signed a three-year clinical manufacturing agreement with GSK, a science-led global healthcare company. Under the agreement, HCATS will manufacture GSK’s SPEAR T-cell receptor therapy targeting NY-ESO-1 for the US, Canadian and European trials. NY-ESO is ...
    All Posts

    Subscribe to Our Email Distribution List
    © 2024 Minaris Regenerative Medicine   |  Privacy Policy   |  Imprint